AircraftExchange Continues to Dominate as the Premier On-line Marketplace for Preowned BizJets
'The remarkable success of AircraftExchange stems from the trust and confidence placed in our IADA members.' — IADA Executive Director Lou Seno
LOS ANGELES, CA, UNITED STATES, March 3, 2025 / EINPresswire.com / -- AircraftExchange.com, the premier online marketplace for preowned business aircraft, powered by the International Aircraft Dealers Association (IADA), continues to set the standard for buyers and sellers of preowned business aircraft.
With its unwavering commitment to quality, trust and transparency, AircraftExchange has become the preferred resource for discerning clientele seeking the most reliable aircraft transactions. Only aircraft listed by IADA dealers are accepted on the site, which is available to the buying public.
'The remarkable success of AircraftExchange stems from the trust and confidence placed in our IADA members,' said IADA Executive Director Lou Seno. 'With an unmatched selection of verified aircraft and a team of professionals committed to ethical and transparent business practices, IADA's AircraftExchange has firmly established itself as the industry's leading on-line listing platform.'
With unprecedented growth and market impact over the past year, AircraftExchange has continued its rapid rise in popularity, reinforcing its dominance in the preowned business aircraft marketplace:
Significant User Growth – AircraftExchange attracted 900,000 users in the past year, a testament to its growing influence, and a 72% annual increase.
Record-Breaking Engagement – The platform generated 2.6 million page views, reflecting heightened buyer and seller activity.
Increased Lead Generation – In the past year, IADA-Accredited Dealers reported a 35% increase in preowned aircraft marketing leads through AircraftExchange.
Dominance in North America – AircraftExchange remains the top marketplace for the most attractive preowned business aircraft listings throughout North America.
Global Expansion – IADA promoted AircraftExchange with an international digital advertising campaign, driving nearly a million global advertising clicks.
Enhanced Dealer Connectivity – An innovative exclusive IADA member feature now quickly notifies 600 IADA dealer/broker team members when an IADA dealer has been contracted to find a specific aircraft model with certain features.
Expansive Inventory – Currently, AircraftExchange lists some 700 aircraft, including 220 mid-size business jets, all vetted and offering buyers an unparalleled selection.
Unmatched Transaction Volume – In the past year, IADA members and AircraftExchange facilitated over $15 billion in transactions, underscoring its role as the most trusted marketplace for preowned business aircraft.
Personal Dashboard – AircraftExchange users can create their own personal dashboards to track the availability of specific aircraft with specific features that they are seeking.
AircraftExchange differentiates itself from other listing services by exclusively featuring verified listings from IADA dealers and brokers. This select approach guarantees no bait-and-switch tactics, providing buyers with the ultimate confidence in their transactions. AircraftExchange marketing search portal is the only site where every aircraft listed for sale is represented by an IADA-Accredited Dealer. AircraftExchange enables users to create a confidential dashboard of business jets for sale, filtered based on their features and amenities, class size, age, and price. Users can browse through data-rich listings for available business aircraft. For more info go to https://aircraftexchange.com.
About IADA
The International Aircraft Dealers Association (IADA) is a professional trade organization that sets the standard for excellence in the aircraft resale industry. IADA members are among the most experienced and respected professionals in the field, committed to maintaining the highest levels of integrity, transparency, and expertise. IADA-Accredited Dealers undergo rigorous vetting and continuous re-accreditation, ensuring that they meet the highest standards of professional conduct and service. IADA Product & Services members are verified to assure the highest ethical standards and levels of experience. For more information, visit https://iada.aero.
Jim Gregory for IADA
James Gregory Consultancy llc
X
Other
Legal Disclaimer:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
BreachLock Secures Global CREST Accreditation for Penetration Testing, Expanding Access to Trusted Security Testing Worldwide
NEW YORK, Aug. 13, 2025 /PRNewswire/ -- BreachLock, a global leader in offensive security, announced today it has elevated its CREST membership and accreditation from regional to global status, underscoring its commitment to delivering world-class penetration testing services across the globe. CREST, the Council of Registered Ethical Security Testers, is an internationally recognized accreditation body that upholds the highest standards in the cybersecurity industry. CREST assesses penetration testing service providers' service-related policies, processes, and procedures through rigorous technical assessments and demanding audits, binding all accredited members to its strict code of conduct. Achieving global CREST accreditation marks a major milestone for BreachLock, showcasing its proven track record, expanding international reach, and unwavering commitment to delivering quality and consistency in penetration testing services worldwide. "This achievement is more than just a badge. It affirms to our global client base that BreachLock delivers the same level of quality, precision, and consistency no matter where in the world they operate," expressed Seemant Sehgal, Founder & CEO of BreachLock. "As threats grow more sophisticated with agentic offensive security, we deliver scalable, accredited testing anywhere our clients operate — maintaining the high standards that have earned their trust for seven years. We are the only vendor that covers both external professional services and offensive security platforms for internal pen testing teams." BreachLock continues to lead the evolution of penetration testing by delivering Penetration Testing as a Service (PTaaS) at scale through its Unified Platform, which pairs next-generation security testing automation with CREST-accredited human expertise to maximize its scalability, flexibility, and speed. This approach supports continuous and on-demand testing across diverse environments, including applications, APIs, internal and external networks, cloud infrastructures, IoT devices, and even large language models (LLMs). By combining automated testing with expert validation, BreachLock helps organizations identify, prioritize, and remediate risks faster, regardless of where their assets reside. Elevation to Global accreditation further underscores the company's ability to consistently deliver this standard of service worldwide. Learn more about BreachLock's CREST-accredited penetration testing services today at About BreachLockBreachLock is a global leader in offensive security, delivering scalable and continuous security testing. Trusted by global enterprises, BreachLock provides human-led and AI-powered Attack Surface Management, Penetration Testing as a Service (PTaaS), Red Teaming, and Adversarial Exposure Validation (AEV) solutions that help security teams stay ahead of adversaries. With a mission to make proactive security the new standard, BreachLock is shaping the future of cybersecurity through automation, data-driven intelligence, and expert-driven execution. Know Your Risk. Contact BreachLock today! Media Contact Megan Charrois Senior Marketing Executive megan.c@ View original content to download multimedia: SOURCE BreachLock Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
07-08-2025
- Business Upturn
Allsup Veterans Appeal Team Advocates For Veterans Amid Low Ratings, Denials, Greater Complexity In VA Appeals
Belleville, Illinois, Aug. 07, 2025 (GLOBE NEWSWIRE) — Allsup, a nationwide disability benefits advocate, and its Allsup Veterans Appeals℠ (AVA) are committed to supporting veterans as they navigate low disability ratings, compensation claim denials, and increasing complexity in the VA appeals process. While the U.S. Department of Veterans Affairs (VA) announced it processed more than 2 million disability compensation claims in fiscal year 2024—the highest volume in its history—many veterans are receiving decisions that don't accurately reflect the severity of their service-connected conditions. Completing higher claims volume alone has not solved the deeper issues veterans face when seeking fair outcomes, according to Brett Buchanan, U.S. Army veteran and director of Allsup Veterans Appeals. 'Many veterans with multiple service-connected conditions are facing low ratings that fail to reflect the true severity of their disabilities,' Buchanan explained. 'This can result in veterans not receiving the compensation they deserve. We're here to guide them through the appeal process with the goal of a fair and accurate rating for their service.' AVA, a division of Allsup, focuses on helping veterans appeal their VA compensation claims and navigate the evolving VA disability system. While the VA's processing improvements mark important progress, the need for expert support during the appeals process remains critical. The Appeals Modernization Act (AMA) created three distinct pathways to appeal a decision, each with different timelines, evidentiary standards and review options. Despite gains in initial decision processing, veterans are often left frustrated and confused by the VA's complex appeals structure. Selecting the right path is essential to avoid delays and improve outcomes. 'Veterans need expert guidance to select the right appeal path, avoid common mistakes and ensure their cases are presented in the strongest way possible,' Buchanan said. 'The VA disability appeals process can feel overwhelming for veterans because of this variety of options and the critical value of these benefits for themselves and their families.' VA appeal paths include a Higher-Level Review, where a senior reviewer re-examines the existing record without new information; a Supplemental Claim, which allows veterans to submit new and relevant evidence; and an appeal to the Board of Veterans' Appeals (BVA), offering three options— Direct Review, Evidence Submission or a Hearing. AVA's VA-accredited Claims Agents provide expert support by: Explaining eligibility requirements and what evidence is needed to support a claim. Providing guidance on how to apply for disability benefits and what to expect after filing. Assisting with denials and appeals, including selecting the appropriate path: Higher-Level Review, Supplemental Claim, or appeal to the Board of Veterans' Appeals. Clarifying how VA ratings work and what to do if a rating appears too low. Offering representation from VA-accredited claims agents with the proper credentials to advocate for veterans. Veterans pay nothing upfront—Allsup Veterans Appeals receives payment from retroactive benefits. With more 13 years of experience and a 97 percent success rate for those who complete the VA appeals process with us, AVA continues to provide strategic and personalized appeals support for veterans seeking the benefits they have earned. Veterans denied compensation or dissatisfied with a VA decision in the last year, can contact Allsup Veterans Appeals for a free consultation and expert guidance on how to proceed. If you or a veteran you know has questions about VA disability benefits, please call 888-372-1190 or visit ABOUT ALLSUP Allsup and its subsidiaries provide nationwide Social Security disability, veterans disability appeal, disability financial solutions, return to work, and healthcare benefits services for individuals, their employers and insurance carriers. Allsup professionals deliver specialized services supporting people with disabilities and seniors so they may lead lives that are as financially secure and as healthy as possible. Founded in 1984, the company is based in Belleville, Illinois, near St. Louis. Learn more at and follow Attachment Brett Buchanan, U.S. Army veteran and director of Allsup Veterans Appeals Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
30-07-2025
- Business Wire
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company's PanTracer portfolio. PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring, empowering data-driven decisions even when tumor tissue is limited or unavailable. 'The launch of our liquid biopsy test positions us at the forefront of the precision oncology market,' said Tony Zook, Chief Executive Officer, NeoGenomics. 'As demand grows for faster, less invasive, and more accessible genomic testing, PanTracer LBx expands our addressable market, enhances our clinical portfolio, and opens new revenue streams in both therapy selection, trial matching, and disease monitoring. It's a strategic milestone that underscores our commitment to sustainable growth and clinical leadership.' Using circulating tumor DNA (ctDNA) from a simple blood draw, PanTracer LBx provides access to biomarker information when tissue samples are insufficient or unavailable. The test is designed to offer a seven-day turnaround time and analyze over 500 genes, including MSI and bTMB, to deliver timely, actionable insights. When indicated, it can be ordered as a standalone option, as a reflex when tissue testing fails, or concurrently with tissue analysis. Clinical applications include therapy selection, trial matching, and longitudinal monitoring. PanTracer LBx strengthens NeoGenomics' pan-solid tumor CGP portfolio, working seamlessly with tissue-based options like PanTracer Tissue, providing a testing strategy across a range of solid cancers. Complemented by a broad portfolio of testing services and dedicated clinical support, the launch expands NeoGenomics' position in the growing $3–5 billion liquid biopsy market and advances its goal of delivering deep insights to more patients across diverse care settings. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'can,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the potential impact of PanTracer™ LBx in oncology treatment and clinical trial enrollment. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the extent of use by oncologists and biopharma companies of PanTracer™ LBx, the speed and utility of the results generated, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and in the 'Investors' section of our website at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
